Experimental Mouse Models of Disseminated *Candida auris* Infection

Hong Xin, a Farhan Mohiuddin, b Jensen Tran, b Abby Adams, a Karen Eberle a

a LSU Health Sciences Center New Orleans, New Orleans, Louisiana, USA
b Loyola University New Orleans, New Orleans, Louisiana, USA

**ABSTRACT** Disseminated candidiasis is a life-threatening disease and remains the most common bloodstream infection in hospitalized patients in the United States. Despite the availability of modern antifungal therapy, crude mortality in the last decade has remained unacceptably high. In particular, *Candida auris* is a multidrug-resistant, health care-associated fungal pathogen and has recently emerged as the first fungal pathogen to cause a global public health threat. A reliable animal model for disseminated *C. auris* candidiasis is therefore needed to study the unique aspects of this little-known host-pathogen interaction. In this study, we established an inbred A/J intravenous model as an appropriate model for human disseminated *C. auris* infection. We found that C5 deficiency in A/J mice results in a complex phenotype characterized by rapid fungal proliferation in target organs and the development of a unique and rapidly fatal response. In contrast, C57BL/6J mice and mice deficient in neutrophil elastase (NE/H11002/H11002) survived high-dose *C. auris* intravenous challenge, even with cyclophosphamide (CY)-induced immunosuppression. Our study is the first to provide insight into the role of C5 in the host responses to *C. auris* invasive infection and establishes an inbred A/J mouse model of systemic *C. auris* infection without CY-induced immunosuppression.

**IMPORTANCE** In the last decade, *Candida auris* has emerged globally as a multidrug-resistant fungal pathogen. Although *C. auris* was initially isolated from the external ear canal, it can cause outbreaks of invasive infections with very high mortality and comorbidities. Recent reports highlight the ongoing challenges due to organism misidentification, high rates of multifungal drug resistance, and unacceptably high patient mortality. The assessment of *C. auris* virulence in a specific genetic deficiency mouse model of invasive *C. auris* infection in this study contributes to the little knowledge of host defense to *C. auris* infection, which holds promise as a model for investigating the pathogenesis of *C. auris* invasive infection, exploring the immune responses elicited by the fungus, evaluating the possible induction of immunity to the infection, and targeting candidates for an antifungal vaccine.

**KEYWORDS** disseminated candidiasis, *Candida auris*, neutrophil elastase (NE), complement, *Candida*, candidiasis, immunocompromised hosts, mouse models

Since 2009, *Candida auris* has been an emerging fungus that presents a serious global health threat. This novel *Candida* species was initially isolated from the external ear canal of a patient in Japan. This fungus causes deep-seated invasive infections with a very high death rate and causes mainly bloodstream, wound, and ear infections (1, 2). Indeed, *C. auris* is the very first fungal pathogen to cause a global public health threat (3).

Little is known about the virulence mechanisms that lead to the high transmissibility of *C. auris* to cause invasive disease following introduction into the human skin or gastrointestinal (GI) tract. Understanding host defense mechanisms and fungal viru-
Neutrophils are critical for the control of numerous invasive fungal infections, including candidiasis. Neutropenia is one of the most common risk factors for the development of hematogenously disseminated candidiasis in humans (11, 12), in which the mortality is above 50% despite antifungal therapy (13–16). Recently, the Nett group reported that evasion of neutrophil attack explains the virulence of C. auris (3). Unlike many fungal infections, neutropenia has not been reported as a common risk factor for C. auris infection (17, 18), which prompted us to explore if the interaction between neutrophils and C. auris accounts for the unexplained virulence of this emerging pathogen. Neutrophil elastase (NE) is an important component of neutrophil extracellular traps (NET) with a role in immunity against fungal infection, and NE has been implicated in the host defense against microbial or fungal pathogens using NE-deficient (NE−/−) mice (19–22). Despite its limited virulence compared to that of C. albicans, in vitro assays conducted with human neutrophils showed that C. auris is less effective than C. albicans in triggering neutrophil engulfment and NET production (6).

To clarify the contribution of NE in the defense against C. auris, we first evaluated the virulence of two C. auris isolates in NE-deficient mice (B6.129 × 1-Elanetm1Sds/J, referred to as NE−/−) and wild-type (WT) C57BL/6 mice. AR-0381 is a drug-susceptible East Asian isolate, and AR-0386 is an azole-resistant (Erg11 Y132F) South American one. In a preliminary study, we used both strains to infect BALB/c mice by intravenous challenge with inocula ranging from 5 × 10^5 to 5 × 10^7 cells without achieving mor-
tality. The C57BL/6 background strain by genetic control is more resistant to \textit{C. albicans} systemic infection than is the BALB/c strain. In this study, the survival of both the C57BL/6 and NE\textsuperscript{+/−}/H11002 strains after high-dose infection was unimpaired, suggesting that NE is not essential for survival. The greater susceptibility of A/J mice, a C5-deficient inbred strain, to systemic challenge with \textit{C. albicans} and other non-\textit{albicans Candida} (NAC) species \cite{23} prompted us to investigate whether A/J mice are more susceptible to \textit{C. auris} disseminated infection. Here, we conducted a comparative study of the survival and organ CFU of invasive \textit{C. auris} in C57BL/6, NE\textsuperscript{+/−} and A/J mice.

We found that C5 deficiency in A/J mice results in a phenotype characterized by rapid fungal proliferation in target organs and the development of a unique and rapidly fatal \textit{(within 24 to 48 h)} response. In contrast, C57BL/6J and NE\textsuperscript{+/−} mice survived high-dose \textit{C. auris} challenge even with immunosuppressant (CY) treatment.

**RESULTS**

**Comparison of \textit{C. albicans} and \textit{C. auris} virulence in NE\textsuperscript{+/−} and C57BL/6 mice.** As NE is an important serine protease implicated in antifungal immune responses \cite{3}, we first evaluated the virulence of \textit{C. auris} in NE\textsuperscript{+/−} and its wild-type C57BL/6 mice. Initial experiments were conducted to challenge mice of both strains with high doses of \textit{C. auris} intravenously (i.v.). A lethal dose of \textit{C. albicans} SC 5314 (5 × 10^5 cells) was used as a positive control to induce acute invasive candidiasis, as well to provide a virulent comparison to \textit{C. auris}. Mice were inoculated i.v. with \textit{C. auris} (2 × 10^8 cells) and observed twice daily for 20 days for morbidity and mortality. As shown in Fig. 1, all mice...
inoculated with *C. auris* survived and appeared to be clinically normal. In contrast, systemic infection with *C. albicans* (5 × 10⁸ cells) resulted in 80 to 100% mortality by 15 days postinfection, which was associated with clinical signs of disease, including weight loss, lethargy, and a ruffled appearance. It is important to note that in NE/H11002 mice, the fungal burden of *C. auris* in both targeted organs, the kidneys and brain, is higher than that in wild-type C57BL/6 mice. These results show that while NE may contribute to antifungal immunity, it is not required for survival. We tested two clinical isolates of *C. auris* (AR-0381 and AR-0386) for their lethality in mice. Neither strain showed mortality in mice.

**Comparison of virulence of *C. auris* in CY-induced immunosuppressed C57BL and NE−/− mice.** Immunocompromised patients are the highest-risk group for acquiring *C. auris* systemic infection. With the aim of mimicking the clinical situations in humans, experimental invasive *C. auris* infections were induced in both C57BL/6 and NE−/− mice rendered immunocompromised by pretreatment with cyclophosphamide (24–26). We evaluated two different clinical isolates of *C. auris* (AR-0381 and AR-0386) for their lethality in a CY-treated immunosuppressed mouse model of both strains with different doses ranging from 2 × 10⁷ to 2 × 10⁸ cells; only the high-intravenous-inoculum 2 × 10⁸ cells/mouse dose of *C. auris* AR-0386 showed 20% mortality in the mice. Therefore, in the following experiments, the AR-3860 strain was our focus and was used for virulence testing in different mouse strains of a genetic background. The survival data show that CY-induced immunosuppressed mice of both strains are more susceptible to *C. auris* AR-0386; however, they remain resistant against systemic infection by *C. auris*, with only 20% mortality observed by 20 days postinfection (Fig. 2). Importantly, extending the observation period to 30 days postinfection did not change the percent mortality.

**Evaluation of *C. auris* virulence in naive and CY-treated immunosuppressed A/J mice.** Analyses of the pathophysiology and host responses to acute *C. albicans* and to NAC infection, as demonstrated by our group and others, show that A/J mice are extremely sensitive to invasive *Candida* infection (27–29). The increased susceptibility of A/J mice to systemic challenge with *Candida* prompted us to investigate whether A/J mice are more susceptible to *C. auris* disseminated infection. To do this, we first tested two inoculum sizes of a *C. auris* isolate in both naive and CY-treated A/J mice. Compared to C57BL/6 and NE−/−, both naive and CY-treated immunosuppressed A/J mice are much more susceptible to *C. auris*. After intravenous challenge with half the inoculum of organisms (1 × 10⁸ cells) used in C57BL and NE−/− mice, 100% mortality was observed in naive A/J mice within 8 days even without CY pretreatment (Fig. 3). Particularly, an intravenous dose of 2 × 10⁸ *C. auris* cells showed 100% mortality in A/J mice. **FIG 2** Immunosuppressed intravenous mouse models of *C. auris* disseminated infection. C57BL/6 and NE−/− mice received a 200-mg/kg dose of cyclophosphamide (CY) i.p. on day −3. Prolonged neutropenia was maintained by giving each animal a 150-mg/kg dose of CY i.p. every 7 days after infection. On day 0, mice were intravenously infected with 2 × 10⁸ viable *C. auris* cells in 0.1 ml DPBS. As controls, mice without CY treatment were challenged with the same dose of *C. auris* cells at the same time. There is no significant difference in the survival of the two strains with and without CY-induced immunosuppression (P = 0.45). Survival times were statistically evaluated by the Kaplan-Meier statistic (GraphPad Prism, version 7), and P values less than 0.05 were considered statistically significant.
mice pretreated with CY within 48 h. With the same inoculum challenge and CY treatment, C57BL/6 and NE/H11002/H11002 mice are resistant to C. auris bloodstream infection with 80 to 100% survival. After two independent experiments, we developed an naive inbred A/J mouse infection model by screening two different clinical isolates of C. auris (0381 and 0386) for their lethality in mice (data not shown). We used a CY-treated BALB/c i.v. model challenged with either strain and only achieved 20% mortality with 0381 and 40% with 0386. Additionally, 0381 strain has a poor growth rate that was lower than that of the 0386 strain. Due to the lower virulence of 0381 compared to that of 0386 in our previous study, we then focused on testing C. auris 0386 in all the challenge experiments in this study.

Influence of CY-induced immunosuppression on fungal burdens in targeted organs during the course of C. auris invasive infection. Unlike C. albicans, C. auris does not induce a lethal phenotype in WT C57BL/6 and NE−/− mice, even with infections of high inoculum. In this study, we compared the effect of CY-induced immunosuppression on the outcome of C. auris systemic infection in NE−/−, WT C57BL/6, and A/J mice. We infected mice with or without CY pretreatment and terminated the experiment at 48 h postinfection. The CFU counts in the organs of cyclophosphamide-treated mice of C57BL/6 and NE−/− mice were higher than those in mice without CY treatment. C5-deficient A/J mice treated with CY had the most CFU in all targeted organs compared to other groups (Fig. 4A to C). Naïve A/J mice always had higher CFU counts than did CY-treated C57BL/6 and NE−/− mice, and this was independent of host CY-induced immunosuppression. In particular, A/J mice had significantly higher (P < 0.01) numbers of yeast in the brain than did C5-sufficient strains, where only 1 or 2 out of 5 in the C57BL/6 (with and without CY treatment) groups had detectable CFU and 2 out of 5 in NE−/− groups had detectable CFU in the brain. However, all A/J mice, regardless of the CY-induced immunosuppression status, had high fungal burden in the brain (Fig. 4D).

DISCUSSION
A reliable animal model for disseminated C. auris infection is critical for investigating the unique aspects of this little-known host-pathogen interaction. First, to determine the contribution of the antimicrobial molecule neutrophil elastase (NE) in combating C. auris invasive infection, we used mice with deficient NE (NE−/−) and their wild-type control C57BL/6 mice challenged with high doses of C. auris. Interestingly, the survival of both groups after infection was unimpaired, suggesting that NE is not essential for survival here. However, NE−/− mice had a higher fungal burden in all the targeted organs than did wild-type controls, indicating a partial contribution of NE to fungal
immunity. Consistent with reports by other groups, our study also showed a higher pathogenicity for *C. albicans* over *C. auris*. Most groups asserted that *C. auris* could not effectively infect and disseminate in mice unless they were immunocompromised (2). In our study, a larger *C. auris* inoculum size (2 × 10⁷ yeast cells/animal) was administered compared to the 3 × 10⁷ dose used by others, while both C57BL/6J and NE/H11002 strains remained resistant, as measured by survival following intravenous injection of *C. auris* blastospores.

With the aim of mimicking the clinical situations in humans with cancer chemotherapy, experimental systemic *C. auris* infections were also induced in C57BL/6 and NE−/− mice rendered immunocompromised by pretreatment with cyclophosphamide, the most commonly used immunosuppressant for immunosuppressed animal models. The immunosuppressed mice were more susceptible, with increased fungal burdens in targeted organs; however, they survived and tolerated a higher kidney fungal burden without clearing the infection, where 80% survival in both strains was observed by 20 days postinfection. Fungal burden increased in targeted organs after C57BL/6 and NE−/− mice treated with CY; however, the increased fungal replication did not dramatically affect survival. Therefore, an assessment of susceptibility to *C. auris* using intravenous C57BL/6 and NE−/− mouse models has been limited to CFU in targeted organs and interference with immunosuppressant drugs. Since the inbred A/J mouse strain is exquisitely sensitive to infection with *C. albicans*, and since we have successfully established the A/J CY-treated immunosuppressed mouse model for *Candida glabrata* disseminated candidiasis (23), we then developed a hematogenous model of *C. auris* infection in naive inbred A/J mice to study the *in vivo* virulence of *C. auris* that may lead to death without CY-induced immunosuppression. Our results showed that

![FIG 4](image-url)
A/J mice were significantly more susceptible than were the other two mouse strains to *C. auris* and showed outcomes of a typical systemic infection of candidiasis. An intravenous $1 \times 10^6$ inoculum size of *C. auris* already showed 100% mortality within 8 days in A/J inbred mice without immunosuppressant treatment. Additionally, CY-treated A/J mice died rapidly within 48 h. Therefore, the A/J naive mouse model can be considered a valuable model of human disseminated *C. auris* infection. Importantly, this study represents the first demonstration of this relationship of both NE$^{-/-}$ and A/J mice with *C. auris*.

In our preliminary study, we investigated the differential susceptibilities of inbred A/J, BALB/c, and C57BL/6J (B6) strains to acute infection with *C. albicans* (23). The A/J mouse strain is exquisitely sensitive to candidiasis, there are high fungal loads in target tissues, and rapid death occurs within 48 h following intravenous injection of $5 \times 10^5$ cells/0.1 ml *C. albicans* SC5314 blastospores. On the other hand, BALB/c mice survive up to 1 to 2 weeks following the same inoculum by i.v. infection and ultimately die of kidney failure; C57BL/6J mice were more resistant and died within 2 to 3 weeks with the inoculum of $1 \times 10^5$ cells/ml. The Mullick group reported that in A/J mice, tissue damage is associated with increased replication of *Candida* spp. at all targeted organs, with the kidney having the highest fungal burden. However, histological and biochemical analyses showed that it is the heart that suffers the worst damage, which is due to significant leukocyte infiltration in the vicinity of *Candida* hyphae in the heart. Cell infiltration then resulted in strong proinflammatory activity by activating many cytokines and chemokines. Therefore, the heart is the organ that is most affected, and it ultimately fails in C5-deficient mice (30). That is the case with *C. albicans*; however, we did not know if it is the same with *C. auris*. We have evaluated three cytokines, tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and monocyte chemotactic protein 1 (MCP-1), in serum samples from A/J mice 24 to 48 h postchallenge by the use of cytokine enzyme-linked immunosorbent assay (ELISA) kits from BD Biosciences. There were no significantly elevated levels of any cytokine in the sera of A/J mice following infection.

Furthermore, in mouse models of *Candida* invasive infection, susceptibility is under a complex genetic control that affects the onset of infection, type and severity of disease developed, and associated pathologies. Inbred mouse strains vary widely in their degree of innate susceptibility to systemic candidiasis, being either highly susceptible (A/J and DBA/2) or highly resistant (C57BL/6J). Due to genetic resistance, we have tried but failed to establish acute systemic candidiasis with 80 to 100% mortality in BALB/c, C57, or NE$^{-/-}$ mice. Therefore, by use of a highly susceptible A/J strain for a CY-induced immunosuppressed infection model, we surprisingly established a naive A/J model for *C. auris* invasive infection. This systemic infection without CY-induced immunosuppression that leads to acute invasive candidiasis is more suitable for the evaluation of immune responses or comparison of the pathogenicity of *C. albicans* strains without the interference of the consequences of immunosuppression.

As opposed to the C57BL/6J and NE$^{-/-}$ mouse strains, the A/J mouse strain carries a loss-of-function mutation in the structural gene for the C5 component of the complement pathway (26, 27). Studies by our group show that C5 deficiency impairs susceptibility to NAC infections in the A/J strain (23), which further showed extreme susceptibility to *C. auris* invasive infection in this study. C5 plays several critical roles in the host response to infection, including target lysis and phagocyte recruitment. The central role of anaphylatoxin C5a in augmenting host proinflammatory cytokine production upon contact with *C. albicans* has been reported (29, 31), which may indicate a similar role for the complement system in the anti-*C. auris* host defense in mice in this study. The greater susceptibility of A/J mice to *C. auris* disseminated infection might also be associated with an exaggerated inflammatory response (23), indicating that the balance between pro- and anti-inflammatory mediators is crucial for host survival.

Taking together the data provided by us and other groups by the use of experimental mouse models, we conclude that *C. auris* exhibits less virulence than do *C. albicans* isolates. Nevertheless, *C. auris* is a multidrug-resistant fungus rapidly spreading
worldwide as an agent of hospital-associated infections with cruel morbidity and mortality. Assessment of C. albicans virulence in the A/J mouse strain in this study contributes to the knowledge of the host defense to C. auris infection. We have used A/J mice lacking C5 to examine its role in antifungal immunity and have shown that this complement component is essential for resistance to systemic infections with C. auris. Therefore, the A/J mouse holds promise as a model for investigating the pathogenesis of C. auris invasive infection, exploring the immune responses elicited by the fungus, evaluating the possible induction of immunity to the infection, and targeting candidates for antifungal vaccines.

MATERIALS AND METHODS

**Candida strains and culture conditions.** Three isolates of Candida were used to induce systemic infection in mice. C. albicans SC5314 (ATCC MYA-2878), C. auris AR-0381 (CDC), and C. auris AR-0386 (CDC) were grown as stationary-phase (24-h) yeast cells in glucose-yeast extract-peptone (GYEP; 2% glucose, 1% peptone, 0.3% yeast extract) broth at 37°C. Candida yeast cells were washed and suspended to the appropriate cell concentration (5 × 10^5/ml, 1 × 10^5/ml, or 2 × 10^5/ml) in Dulbecco’s phosphate-buffered saline (DPBS; Sigma) and used to infect mice intravenously (i.v.), as described previously (32, 33).

**Mice.** Neutrophil elastase-deficient (NE^-/-) mice on a C57BL/6 background (B6.129X1-Elane^m1Sds/J, 006112) and female 8-week-old WT C57BL/6J (000664) mice were obtained from JAX. A/J female 8-week-old mice (National Cancer Institute Animal Production Program, Frederick, MD) were used throughout. Mice were maintained in our AAALAC-certified animal facility, and all animal experiments were performed using a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the LSU Health Sciences Center (LSUHSC).

**Immunosuppression.** For CY-induced immunosuppressed mouse models, before challenge, C57BL/6, NE^-/-, and A/J mice were immunosuppressed by intraperitoneal (i.p.) injection of a 200-mg/kg dose of cyclophosphamide (CY; Sigma-Aldrich) at day −3. The i.p. injection (150 mg/kg) was repeated every 7 days after infection (i.e., at days 7, 14, 21, and 28 postinfection) in order to maintain leukocytopenia and low neutrophil counts for the entire experimental procedure. This regimen has been shown to render mice neutropenic (absolute neutrophil count, <500 cells/mm^3) within 3 to 4 days of the first cyclophosphamide dose, and neutropenia lasted until the termination of the experiments (up to day 30) (4, 23, 24). Total leukocyte and differential cell counts were determined on a hemacytometer and by Wright-Giemsa staining. Leukocyte and differential counts from peripheral blood were monitored every other day to verify the induction of leukocytopenia. The body weights of the mice were also measured daily and compared during the entire experimental period after the first CY or DPBS injection.

**Fungal challenge dose and assessment of protection.** Immunocompetent and CY-treated immunosuppressed mice and age- and sex-matched normal control mice (n = 5 in each group) were injected intravenously with different doses of live *C. auris* yeast cells (1 × 10^9, 2 × 10^9, or 1 × 10^9/ml DPBS) and *C. albicans* yeast cells (5 × 10^6 in 0.1 ml DPBS). The challenged mice were monitored for the development of a moribund state, defined as being listless, disinterested in food or water, and nonreactive to finger probing. At that time, each mouse was sacrificed, and kidneys, hearts, and brains were homogenized in DPBS and plated onto nutrient agar to determine the CFU. All experiments were performed in duplicate. Tissue burden and mortality rate were used as virulence markers.

**Statistical analysis.** Survival times were statistically evaluated by the Kaplan-Meier statistic (Graph-Pad Prism, version 7), and statistical significance was subsequently calculated for each preset time point of analysis. All fungal burden data were analyzed by a multivariate analysis of variance (MANOVA). This multivariate analysis allowed for correlations of the CFU obtained from organs within the same animal to be determined. All statistical tests were performed at a 5% significance level.

ACKNOWLEDGMENTS

This research was supported by the Department of Defense CDMRP award PR171482.

We thank the Louisiana State University Health Sciences Center (LSUHSC) for support of our research.

REFERENCES

1. Azar MM, Turbett SE, Fishman JA, Pierce VM. 2017. Donor-derived transmission of Candida auris during lung transplantation. Clin Infect Dis 65:1040–1042. https://doi.org/10.1093/cid/cix460.
2. Osei Sekyere J. 2018. Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbioligenpen 7:e00578. https://doi.org/10.1082/mbio.3.578.
3. Johnson CJ, Davis JM, Huttenlocher A, Kernien JF, Nett JE. 2018. Emerging fungal pathogen Candida auris evades neutrophil attack. mBio 9:e01403-18. https://doi.org/10.1128/mBio.01403-18.
4. Segal E, Frenkel M. 2018. Experimental in vivo models of candidiasis. J Fungi 4:21. https://doi.org/10.3390/jof4010021.
5. Ashman RB. 1998. Candida albicans: pathogenesis, immunity and host defense. Res Immunol 149:281–288. https://doi.org/10.1016/S0923-2494(98)80752-9.
6. Rossato L, Colombo AL. 2018. Candida auris: what have we learned about its mechanisms of pathogenicity? Front Microbiol 9:3081. https://doi.org/10.3389/fmicb.2018.03081.
7. Fakhim H, Vaezi A, Dannaoui E, Chowdhary A, Nasiry D, Faeli L, Meis JF,
Badali H. 2018. Comparative virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model. Mycoses 61:377–382. https://doi.org/10.1111/myc.12754.
8. Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, Maor Y, Tarabia J, Schechner V, Finn T. 2017. Telomeric-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis 23:195–203. https://doi.org/10.3202/eid2302.161486.
9. Wang X, Bing J, Zheng Q, Zhang F, Liu J, Yue H, Tao L, Du H, Wang Y, Wang H, Huang G. 2018. The first isolate of Candida auris in China: clinical and biological aspects. Emerg Infect Dis 7:1–9. https://doi.org/10.1038/s41426-018-0095-0.
10. Borman AM, Szekely A, Johnson EM. 2016. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere 1:e00189-16. https://doi.org/10.1128/mSphere.00189-16.
11. Filler SG, Edwards JE. 1995. When and how to treat serious candidal infections: concepts and controversies. Curr Clin Top Infect Dis 15:1–18.
12. Chung JW, Lee SO, Choi SH, Woo JH, Ryu J, Kim YS, Kim NJ. 2006. Risk factors and outcome for breakthrough candidemia in patients with cancer. Mycoses 49:114–118. https://doi.org/10.1111/j.1439-0507.2006.01198.x.
13. Dimopoulos G, Ntziora F, Rachiots G, Armaganidis A, Falagas ME. 2008. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 106:523–529. https://doi.org/10.1213/ane.0b013e3181607262.
14. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino M, Chapman S, Horowitz HW, Edwards JE, Dismukes WE. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37:634–643. https://doi.org/10.1086/376906.
15. Badali H, Hashemizadeh Z. 2014. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J Med Res 139:195–204.
16. Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. 2014. Invasive fungal infections in the ICU: how to approach, how to treat. Molecules 19:1085–1119. https://doi.org/10.3390/molecules19011085.
17. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govindarajan N, Mangino M, Chapman S, Horowitz HW, Edwards JE, Dismukes WE. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37:634–643. https://doi.org/10.1086/376906.
18. Chowdhary A, Anil Kumar V, Sharma A, Prakash A, Agarwal K, Babu R, Dinesh KR, Karim S, Singh SK, Hagen F, Meis JF. 2014. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 33:919–926. https://doi.org/10.1007/s10096-013-2071-7.
19. Bianchi M, Nieniec NJ, Siler U, Urban CF, Reichenbach J. 2011. Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J Allergy Clin Immunol 127:1243–1252. https://doi.org/10.1016/j.jaci.2011.01.021.
20. McCormick A, Heesemann L, Wagener J, Marcos V, Hartl D, Loeffler J, Heesemann J, Ebel F. 2010. NETs formed by neutrophils inhibit growth of the pathogenic mold Aspergillus fumigatus. Micobes Infect 12:928–936. https://doi.org/10.1016/j.micinf.2010.06.009.
21. Reeves EP, Lu H, Jacobs HL, Messina CGM, Bossover S, Gabello G, Potma EO, Warley A, Roes J, Segal AW. 2002. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 416:291–297. https://doi.org/10.1038/416291a.
22. Tkaclevic J, Novelli M, Phylactides M, Iredale JP, Segal AW, Roes J. 2000. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathespin G. Immunity 12:201–210. https://doi.org/10.1016/S1074-7613(00)80173-9.
23. Xin H. 2018. Effects of immune suppression in murine models of disseminated Candida glabrata and Candida tropicalis infection and utility of a synthetic peptide vaccine. Med Mycol 57:745–756. https://doi.org/10.1093/mmy/mmy122.
24. Frenkel M, Mandelblat M, Alatruey-Izquierdo A, Mendlovic S, Semis R, Segal E. 2016. Pathogenicity of Candida albicans isolates from bloodstream and mucosal candidiasis assessed in mice and Galleria mellonella. J Mycol Med 26:1–8. https://doi.org/10.1016/j.jmycmd.2015.12.006.
25. Daniels CC, Rogers PD, Shelton CM. 2016. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther 21:27–35. https://doi.org/10.1086/376906.151198.x.
26. Daniels CC, Rogers PD, Shelton CM. 2016. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther 21:27–35. https://doi.org/10.1086/376906.151198.x.
27. Xin H. 2018. Effects of immune suppression in murine models of disseminated Candida glabrata and Candida tropicalis infection and utility of a synthetic peptide vaccine. Med Mycol 57:745–756. https://doi.org/10.1093/mmy/mmy122.
28. Tuite A, Elias M, Picard S, Mullick A, Gros P. 2005. Genetic control of susceptibility to Candida albicans in susceptible A/J and resistant C57BL/J6 mice. Genes Immun 6:672–682. https://doi.org/10.1038/sj.gene.6364254.
29. Tuite A, Mullick A, Gros P. 2004. Genetic analysis of innate immunity in resistance to Candida albicans. Genes Immun 5:576–587. https://doi.org/10.1038/sj.gene.6364130.
30. Mullick A, Elias M, Picard S, Bourget L, Jovcevski O, Gauthier S, Tuite A, Harakidas P, Bhun C, Massie B, Gros P 2004. Dysregulated inflammatory response to Candida albicans in a C5-deficient mouse strain. Infect Immun 72:5868–5876. https://doi.org/10.1128/IAI.72.10.5868-5876.2004.
31. Cheng S-C, Sprong T, Joosten LAB, van der Meer JWM, Kullberg B-J, Noordhoek S, Dijkstra J, Ylstra BP, Fink GP, van der Heijden P, van der Vossen SH, van der Walt W, Vermaas EW 2007. Mannose-specific IgM protects against murine systemic candidiasis. Infect Immun 75:5832–5840. https://doi.org/10.1128/IAI.00159-06.
32. Han Y, Riesselman MH, Cutler JE. 2000. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannortriose as an IgM protective antibody. Infect Immun 68:1649–1654. https://doi.org/10.1128/IAI.68.3.1649-1654.2000.